Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.40 |
| ▸ | NT5E | P21589 | 6/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498228 | 0.91 | LMNA (0.37) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL5492971 | 0.91 | NT5E (0.38) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL5735963 | 0.90 | LMNA (0.35) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL9404373 | 0.90 | LMNA (0.35) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL9404059 | 0.88 | LMNA (0.34) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL4834707 | 0.87 | PDE4A (0.37) | LMNAADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6386486 | 0.87 | PDE4A (0.37) | LMNAADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL7066425 | 0.85 | LMNA (0.42) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL5498844 | 0.81 | ADORA2A (0.44) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL4950531 | 0.80 | ADORA2A (0.34) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
| EP-2707483-B1 | METHODS AND MATERIALS FOR NUCLEIC ACID MANIPULATION | RWTH AACHEN UNIV (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
| EP-1895841-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | Brigham Young University (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138396-A2 | METHODS FOR SELECTIVE N-9 GLYCOSYLATION OF PURINES | BRIGHAM YOUNG UNIVERSITY, TRANSFER TECHNOLOGY OFFICE (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1090023-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067264-A1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
| EP-0675896-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994014832-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-07 | — | — | WO | disclosed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | LMNA 3844/4885TP53 2623/4885ALDH1A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.